

TEST BANK

LPharmacotherapeutics for Advanced Practice A Practical Approach

Virginia Poole Arcangelo, Andrew M. Peterson, Veronica Wilbur, Tep M. Kang

5th Edition




Table of content

Chapter 1	Issues for the Practitioner in Drug Therapy
Chapter 2	Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
Chapter 3	Impact of Drug Interactions and Adverse Events on Therapeutics
Chapter 4	Principles of Pharmacotherapy in Pediatrics, Pregnancy, and Lactation
Chapter 5	Pharmacotherapy Principles in Older Adults
Chapter 6	Principles of Antimicrobial Therapy
Chapter 7	Pharmacogenomics
Chapter 8	The Economics of Pharmacotherapeutics
Chapter 9	Pharmacotherapy of Pain Management
Chapter 10	Pain Management in Opioid Use Disorder (OUD) Patients
Chapter 11	Cannabis and Pain Management
Chapter 12	Contact Dermatitis
Chapter 13	Fungal, Viral, and Bacterial Infections of the Skin
Chapter 14	Psoriasis
Chapter 15	Acne Vulgaris and Rosacea
Chapter 16	Ophthalmic Disorders
Chapter 17	Otitis Media and Otitis Externa
Chapter 18	Hypertension
Chapter 19	Hyperlipidemia
Chapter 20	Chronic Stable Angina and Myocardial Infarction
Chapter 21	Heart Failure
Chapter 22	Arrhythmias
Chapter 23	Respiratory Infections
Chapter 24	Asthma and Chronic Obstructive Pulmonary Disease
Chapter 25	Gastric, Functional, and Inflammatory Bowel Disorders
Chapter 26	Gastroesophageal Reflux Disease and Peptic Ulcer Disease
Chapter 27	Liver Diseases
Chapter 28	Urinary Tract Infection
Chapter 29	Prostatic Disorders and Erectile Dysfunction
Chapter 30	Overactive Bladder
Chapter 31	Sexually Transmitted Infections
Chapter 32	Osteoarthritis and Gout
Chapter 33	Osteoporosis
Chapter 34	Rheumatoid Arthritis
Chapter 35	Headaches
Chapter 36	Seizure Disorders
Chapter 37	Alzheimer's Disease
Chapter 38	Parkinson's Disease
Chapter 39	Major Depressive Disorder and Bipolar Disorders
Chapter 40	Anxiety Disorders
Chapter 41	Sleep Disorders
Chapter 42	Attention Deficit Hyperactivity Disorder

Chapter 43 Substance Use Disorders

Chapter 44 Diabetes Mellitus

Chapter 45 Thyroid and Parathyroid Disorders

Chapter 46 Allergies and Allergic Reactions

Chapter 47 Human Immunodeficiency Virus

Chapter 48 Organ Transplantation

Chapter 49 Thromboembolic Disorders

Chapter 50 Anemias

Chapter 51 Immunizations

Chapter 52 Smoking Cessation

Chapter 53 Weight Loss

Chapter 54 Contraception

Chapter 55 Menopause

Chapter 56 Vaginitis

Chapter 1 Issues for the Practitioner in Drug Therapy

MULTIPLE CHOICE

1. Nurse practitioner prescriptive authority is regulated by:

- A. The National Council of State Boards of Nursing
- B. The U.S. Drug Enforcement Administration
- C. The State Board of Nursing for each state
- D. The State Board of Pharmacy

ANS: C PTS: 1

2. Physician Assistant (PA) prescriptive authority is regulated by:

- A. The National Council of State Boards of Nursing
- B. The U.S. Drug Enforcement Administration
- C. The State Board of Nursing
- D. The State Board of Medical Examiners

ANS: D PTS: 1

3. Clinical judgment in prescribing includes:

- A. Factoring in the cost to the patient of the medication prescribed
- B. Always prescribing the newest medication available for the disease process
- C. Handing out drug samples to poor patients
- D. Prescribing all generic medications to cut costs

ANS: A PTS: 1

4. Criteria for choosing an effective drug for a disorder include:

- A. Asking the patient what drug they think would work best for them
- B. Consulting nationally recognized guidelines for disease management
- C. Prescribing medications that are available as samples before writing a prescription
- D. Following U.S. Drug Enforcement Administration (DEA) guidelines for prescribing

ANS: B PTS: 1

5. Nurse practitioner practice may thrive under health-care reform due to:

- A. The demonstrated ability of nurse practitioners to control costs and improve patient outcomes
- B. The fact that nurse practitioners will be able to practice independently
- C. The fact that nurse practitioners will have full reimbursement under health-care reform
- D. The ability to shift accountability for Medicaid to the state level

ANS: A PTS: 1

Chapter 2. Pharmacokinetic Basis of Therapeutics and Pharmacodynamic

MULTIPLE CHOICE

1. A patient's nutritional intake and lab work reflects hypoalbuminemia. This is critical to prescribing because:
- A. Distribution of drugs to target tissue may be affected
 - B. The solubility of the drug will not match the site of absorption
 - C. There will be less free drug available to generate an effect
 - D. Drugs bound to albumin are readily excreted by the kidney

ANS: A PTS: 1

2. Drugs that have a significant first-pass effect:
- A. Must be given by the enteral (oral) route only
 - B. Bypass the hepatic circulation
 - C. Are rapidly metabolized by the liver and may have little if any desired action
 - D. Are converted by the liver to more active and fat-soluble forms

ANS: C PTS: 1

3. The route of excretion of a volatile drug will likely be:
- A. The kidneys
 - B. The lungs
 - C. The bile and feces
 - D. The skin

ANS: B PTS: 1

4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of the drug. Storage reservoirs:
- A. Assure that the drug will reach its intended target tissue
 - B. Are the reason for giving loading doses
 - C. Increase the length of time a drug is available and active
 - D. Are most common in collagen tissues

ANS: C PTS: 1

5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug's:
- A. Propensity to go to the target receptor
 - B. Biological half-life
 - C. Pharmacodynamics
 - D. Safety and side effects

ANS: B PTS: 1

6. Azithromycin dosing requires the first day's dose be twice those of the other 4 days of the prescription. This is considered a loading dose. A loading dose:
- A. Rapidly achieves drug levels in the therapeutic range
 - B. Requires four to five half-lives to attain
 - C. Is influenced by renal function

D. Is directly related to the drug circulating to the target tissues

ANS: A PTS: 1

7. The point in time on the drug concentration curve that indicates the first sign of a therapeutic effect is the:

A. Minimum adverse effect level
 B. Peak of action
 C. Onset of action
 D. Therapeutic range

ANS: C PTS: 1

8. Phenytoin requires a trough level be drawn. Peak and trough levels are done:

A. When the drug has a wide therapeutic range
 B. When the drug will be administered for a short time only
 C. When there is a high correlation between the dose and saturation of receptor sites
 D. To determine if a drug is in the therapeutic range

ANS: D PTS: 1

9. A laboratory result indicates the peak level for a drug is above the minimum toxic concentration. This means that the:

A. Concentration will produce therapeutic effects
 B. Concentration will produce an adverse response
 C. Time between doses must be shortened
 D. Duration of action of the drug is too long

ANS: B PTS: 1

10. Drugs that are receptor agonists may demonstrate what property?

A. Irreversible binding to the drug receptor site
 B. Up-regulation with chronic use
 C. Desensitization or down-regulation with continuous use
 D. Inverse relationship between drug concentration and drug action

ANS: C PTS: 1

11. Drugs that are receptor antagonists, such as beta blockers, may cause:

A. Down-regulation of the drug receptor
 B. An exaggerated response if abruptly discontinued
 C. Partial blockade of the effects of agonist drugs
 D. An exaggerated response to competitive drug agonists

ANS: B PTS: 1

12. Factors that affect gastric drug absorption include:

A. Liver enzyme activity
 B. Protein-binding properties of the drug molecule
 C. Lipid solubility of the drug
 D. Ability to chew and swallow

ANS: C PTS: 1

13. Drugs administered via intravenous (IV) route:
 - A. Need to be lipid soluble in order to be easily absorbed
 - B. Begin distribution into the body immediately
 - C. Are easily absorbed if they are nonionized
 - D. May use pinocytosis to be absorbed

ANS: B PTS: 1
14. When a medication is added to a regimen for a synergistic effect, the combined effect of the drugs is:
 - A. The sum of the effects of each drug individually
 - B. Greater than the sum of the effects of each drug individually
 - C. Less than the effect of each drug individually
 - D. Not predictable, as it varies with each individual

ANS: B PTS: 1
15. Which of the following statements about bioavailability is true?
 - A. Bioavailability issues are especially important for drugs with narrow therapeutic ranges or sustained release mechanisms.
 - B. All brands of a drug have the same bioavailability.
 - C. Drugs that are administered more than once a day have greater bioavailability than drugs given once daily.
 - D. Combining an active drug with an inert substance does not affect bioavailability.

ANS: A PTS: 1
16. Which of the following statements about the major distribution barriers (blood-brain or fetal-placental) is true?
 - A. Water soluble and ionized drugs cross these barriers rapidly.
 - B. The blood-brain barrier slows the entry of many drugs into and from brain cells.
 - C. The fetal-placental barrier protects the fetus from drugs taken by the mother.
 - D. Lipid soluble drugs do not pass these barriers and are safe for pregnant women.

ANS: B PTS: 1
17. Drugs are metabolized mainly by the liver via Phase I or Phase II reactions. The purpose of both of these types of reactions is to:
 - A. Inactivate prodrugs before they can be activated by target tissues
 - B. Change the drugs so they can cross plasma membranes
 - C. Change drug molecules to a form that an excretory organ can excrete
 - D. Make these drugs more ionized and polar to facilitate excretion

ANS: C PTS: 1
18. Once they have been metabolized by the liver, the metabolites may be:
 - A. More active than the parent drug
 - B. Less active than the parent drug
 - C. Totally “deactivated” so that they are excreted without any effect
 - D. All of the above

ANS: D PTS: 1

19. All drugs continue to act in the body until they are changed or excreted. The ability of the body to excrete drugs via the renal system would be increased by:
- A. Reduced circulation and perfusion of the kidney
 - B. Chronic renal disease
 - C. Competition for a transport site by another drug
 - D. Unbinding a nonvolatile drug from plasma proteins

ANS: D PTS: 1

20. Steady state is:
- A. The point on the drug concentration curve when absorption exceeds excretion
 - B. When the amount of drug in the body remains constant
 - C. When the amount of drug in the body stays below the MTC
 - D. All of the above

ANS: B PTS: 1

21. Two different pain meds are given together for pain relief. The drug-drug interaction is:
- A. Synergistic
 - B. Antagonistic
 - C. Potentiative
 - D. Additive

ANS: D PTS: 1

22. Actions taken to reduce drug-drug interaction problems include all of the following EXCEPT:
- A. Reducing the dose of one of the drugs
 - B. Scheduling their administration at different times
 - C. Prescribing a third drug to counteract the adverse reaction of the combination
 - D. Reducing the dosage of both drugs

ANS: C PTS: 1

23. Phase I oxidative-reductive processes of drug metabolism require certain nutritional elements. Which of the following would reduce or inhibit this process?
- A. Protein malnutrition
 - B. Iron deficiency anemia
 - C. Both A and B
 - D. Neither A nor B

ANS: D PTS: 1

24. The time required for the amount of drug in the body to decrease by 50% is called:
- A. Steady state
 - B. Half-life
 - C. Phase II metabolism
 - D. Reduced bioavailability time

ANS: B PTS: 1

25. An agonist activates a receptor and stimulates a response. When given frequently over time the body may:
- A. Up-regulate the total number of receptors
 - B. Block the receptor with a partial agonist
 - C. Alter the drug's metabolism
 - D. Down-regulate the numbers of that specific receptor

ANS: D PTS: 1

26. Drug antagonism is best defined as an effect of a drug that:
- A. Leads to major physiologic psychological dependence
 - B. Is modified by the concurrent administration of another drug
 - C. Cannot be metabolized before another dose is administered
 - D. Leads to a decreased physiologic response when combined with another drug

ANS: B PTS: 1

27. Instructions to a client regarding self-administration of oral enteric-coated tablets should include which of the following statements?
- A. "Avoid any other oral medicines while taking this drug."
 - B. "If swallowing this tablet is difficult, dissolve it in 3 ounces of orange juice."
 - C. "The tablet may be crushed if you have any difficulty taking it."
 - D. "To achieve best effect, take the tablet with at least 8 ounces of fluid."

ANS: D PTS: 1

28. The major reason for not crushing a sustained release capsule is that, if crushed, the coated beads of the drugs could possibly result in:
- A. Disintegration
 - B. Toxicity
 - C. Malabsorption
 - D. Deterioration

ANS: B PTS: 1

29. Which of the following substances is the most likely to be absorbed in the intestines rather than in the stomach?
- A. Sodium bicarbonate
 - B. Ascorbic acid
 - C. Salicylic acid
 - D. Glucose

ANS: A PTS: 1

30. Which of the following variables is a factor in drug absorption?
- A. The smaller the surface area for absorption, the more rapidly the drug is absorbed.
 - B. A rich blood supply to the area of absorption leads to better absorption.
 - C. The less soluble the drug, the more easily it is absorbed.
 - D. Ionized drugs are easily absorbed across the cell membrane.

ANS: B PTS: 1

31. An advantage of prescribing a sublingual medication is that the medication is:

- A. Absorbed rapidly
- B. Excreted rapidly
- C. Metabolized minimally
- D. Distributed equally

ANS: A PTS: 1

32. Drugs that use CYP 3A4 isoenzymes for metabolism may:
- A. Induce the metabolism of another drug
 - B. Inhibit the metabolism of another drug
 - C. Both A and B
 - D. Neither A nor B

ANS: C PTS: 1

33. Therapeutic drug levels are drawn when a drug reaches steady state. Drugs reach steady state:
- A. After the second dose
 - B. After four to five half-lives
 - C. When the patient feels the full effect of the drug
 - D. One hour after IV administration

ANS: B PTS: 1

34. Up-regulation or hypersensitization may lead to:
- A. Increased response to a drug
 - B. Decreased response to a drug
 - C. An exaggerated response if the drug is withdrawn
 - D. Refractoriness or complete lack of response

ANS: C PTS: 1